$RCHA,,,Just getting started IMO,,,thanks jobim
Post# of 106843
(Total Views: 88)
Posted On: 07/21/2017 10:24:31 AM
$RCHA,,,Just getting started IMO,,,thanks jobim
Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson's Disease
Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
BEVERLY HILLS, CA--(Marketwired - Jul 18, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, today announced that it has signed a support and collaboration agreement to assist Mega Bridge. Inc., a company which is to be renamed HypGen, Inc., for $100,000 and shares of HypGen common stock.
"HypGen is commencing work on treatments for Parkinson's disease. Certain of the data Rich Pharmaceuticals has amassed for its treatment protocol for Acute Myelocytic Leukemia (AML) will have significant value for HypGen as it moves forward in the regulatory process," said Ben Chang, CEO, Rich Pharmaceuticals.
Under the terms of the agreement, Rich Pharmaceuticals will receive 15 million shares of HypGen Common Stock. Rich Pharmaceuticals plans to dividend a minimum of five million of these shares to its shareholders at such time as the company completes the necessary corporate and regulatory requirements regarding payment of a dividend.
"There is a long tradition in biotechnology to share data when possible because we all have the same aim: To save lives and to prolong productive lives. We are blessed to play a role in that tradition and pleased that our investors will benefit from this agreement," Mr. Chang said.
The terms of the support and collaboration agreement, and a copy of the agreement, were disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 12, 2017, which may be found at www.sec.gov or on the Company's website at www.richpharmaceuticals.com/investor-relations/sec-filings/.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at www.richpharmaceuticals.com
Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson's Disease
Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
BEVERLY HILLS, CA--(Marketwired - Jul 18, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, today announced that it has signed a support and collaboration agreement to assist Mega Bridge. Inc., a company which is to be renamed HypGen, Inc., for $100,000 and shares of HypGen common stock.
"HypGen is commencing work on treatments for Parkinson's disease. Certain of the data Rich Pharmaceuticals has amassed for its treatment protocol for Acute Myelocytic Leukemia (AML) will have significant value for HypGen as it moves forward in the regulatory process," said Ben Chang, CEO, Rich Pharmaceuticals.
Under the terms of the agreement, Rich Pharmaceuticals will receive 15 million shares of HypGen Common Stock. Rich Pharmaceuticals plans to dividend a minimum of five million of these shares to its shareholders at such time as the company completes the necessary corporate and regulatory requirements regarding payment of a dividend.
"There is a long tradition in biotechnology to share data when possible because we all have the same aim: To save lives and to prolong productive lives. We are blessed to play a role in that tradition and pleased that our investors will benefit from this agreement," Mr. Chang said.
The terms of the support and collaboration agreement, and a copy of the agreement, were disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 12, 2017, which may be found at www.sec.gov or on the Company's website at www.richpharmaceuticals.com/investor-relations/sec-filings/.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at www.richpharmaceuticals.com
(1)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280